Drugs / MK8245
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 missed | ||||||
| Phase 1 | NCT00972322 | Aug 2009 → Jan 2010 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 1 | NCT00790556 | Oct 2008 → Sep 2009 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00846391 | Dec 2008 → Aug 2009 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK8245 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00790556 ↗ |
| Action | Inhibit | “liver-specific SCD-1 inhibitor, MK8245” PMID 27392483 ↗ Jul 2016 |
| Modality | Small molecule | — CHEMBL1938870 ↗ |
| Target | SCD | “liver-specific SCD-1 inhibitor, MK8245” PMID 27392483 ↗ Jul 2016 |